GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Other Gross PPE

CSL (ASX:CSL) Other Gross PPE : A$0 Mil (As of Dec. 2023)


View and export this data going back to 1994. Start your Free Trial

What is CSL Other Gross PPE?

CSL's Other Gross PPE for the quarter that ended in Dec. 2023 was A$0 Mil.

CSL's quarterly Other Gross PPE increased from Dec. 2022 (A$0 Mil) to Jun. 2023 (A$4,172 Mil) but then declined from Jun. 2023 (A$4,172 Mil) to Dec. 2023 (A$0 Mil).

CSL's annual Other Gross PPE increased from Jun. 2021 (A$2,791 Mil) to Jun. 2022 (A$3,481 Mil) and increased from Jun. 2022 (A$3,481 Mil) to Jun. 2023 (A$4,172 Mil).


CSL Other Gross PPE Historical Data

The historical data trend for CSL's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Other Gross PPE Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 598.90 2,620.08 2,790.75 3,480.94 4,172.00

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3,480.94 - 4,172.00 -

CSL Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


CSL (ASX:CSL) Business Description

Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.